Education
About Us
Working with TipRanks
Follow Us
PharmaTher Holdings Ltd (TSE:PHRM)
:PHRM
RESEARCH TOOLSreports
PHRM Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.16 - C$0.57
Previous CloseN/A
Volume18.00K
Average Volume (3M)105.13K
Market Cap
C$39.83M
Enterprise ValueC$3.78M
Total Cash (Recent Filing)C$1.55M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Sep 25, 2025EPS EstimateN/A
Last Dividend Ex-Date
Mar 30, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding88,519,066
10 Day Avg. Volume102,860
30 Day Avg. Volume105,134
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-3.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
PharmaTher Holdings Ltd News
Options Prices
Currently, No data available
---
Ownership Overview
17.61% Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
82.39% Public Companies and
Individual Investors
PHRM FAQ
What was PharmaTher Holdings Ltd’s price range in the past 12 months?
PharmaTher Holdings Ltd lowest stock price was C$0.15 and its highest was C$0.57 in the past 12 months.
What is PharmaTher Holdings Ltd’s market cap?
PharmaTher Holdings Ltd’s market cap is C$39.83M.
When is PharmaTher Holdings Ltd’s upcoming earnings report date?
PharmaTher Holdings Ltd’s upcoming earnings report date is Sep 25, 2025 which is in 72 days.
How were PharmaTher Holdings Ltd’s earnings last quarter?
Currently, no data Available
Is PharmaTher Holdings Ltd overvalued?
According to Wall Street analysts PharmaTher Holdings Ltd’s price is currently Overvalued.
Does PharmaTher Holdings Ltd pay dividends?
PharmaTher Holdings Ltd pays a Notavailable dividend of C$0.027 which represents an annual dividend yield of N/A. See more information on PharmaTher Holdings Ltd dividends here
What is PharmaTher Holdings Ltd’s EPS estimate?
PharmaTher Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaTher Holdings Ltd have?
PharmaTher Holdings Ltd has 88,519,066 shares outstanding.
What happened to PharmaTher Holdings Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaTher Holdings Ltd?
Currently, no hedge funds are holding shares in TSE:PHRM
PharmaTher Holdings Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.59%
12-Months-Change
Fundamentals
Return on Equity
-76.00%
Trailing 12-Months
Asset Growth
-50.90%
Trailing 12-Months
Company Description
PharmaTher Holdings Ltd
PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications. Its pipeline also comprises Ketamine Patch that is in Phase I and II clinical trials for treating depression, mental health, complex regional pain syndrome, and pain disorders; and Ketamine Pump, which is in Phase II clinical trial to treat metal health, pain disorders, and surgery/procedure. In addition, the company engages in the development of PHARMAPATCH, a microneedle patch to deliver psychedelics. It has collaboration agreements with LTS Lohmann Therapie-Systeme AG for developing Ketamin microneedle patch; Alcami Corporation to develop Ketamin injectables/infusions; BioRAE, Inc. for the development of Ketamin pumps; Revive Therapeutics Ltd. to develop psilocybin microneedle patch; Gesval S.A. for the development of patented continuous-flow process technology for the preparation of ketamine and ketamine analogs; and PharmaTher's to create a proprietary wearable ketamine delivery solution for mental health, neurological and pain disorders. The company was incorporated in 2019 and is headquartered in Toronto, Canada.